neutralising antibody titres – Communicable Diseases Research

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis

SARS-CoV-2 항체 수준의 종단적 변이와 바이러스 변이체의 출현: 혈청학적 분석

Article

Published on 2022-07-012022-09-11
Journal: The Lancet. Microbe
[Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료법,

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

COVID-19 백신 접종 및 BA.1 돌발 감염은 BA.4 및 BA.5 오미크론 변이체에 대해 덜 효율적인 중화 항체를 유도, 이스라엘, 2022년 3월~6월

Article

Published on 2022-07-012022-09-11
Journal: Eurosurveillance
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

SARS-CoV-2 오미크론 변이체 중화에 필수적인 주요 백신 최소 3회 투여

Article

Published on 2022-05-172022-09-11
Journal: Frontiers in Immunology
[Category] COVID19(2023년), SARS, 변종, 치료기술,

[키워드] AlphaFold AstraZeneca biomolecular modelling coronavirus disease Coronavirus disease-19 COVID-19 Delta different time point different time points Donor donors dose equity Essential followed by Gender generate leading limit of detection Moderna neutralisation Neutralising Antibodies neutralising antibody neutralising antibody titres neutralizing antibody titre Older omicron Omicron variants Pfizer plasma samples reduction in SARS-CoV-2 second dose significantly Spike protein timepoints titre titres Vaccine Vaccines variants variants of concern variants of concern. virus neutralization assay virus neutralization assays were assessed
[DOI] 10.3389/fimmu.2022.883612 PMC 바로가기 [Article Type] Article

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

HIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험

Clinical Trial

Published on 2022-05-012022-09-12
Journal: The Lancet. HIV
[Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed
[DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial

SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study

COVID-19에서 회복된 사람들의 감염 1년 후 SARS-CoV-2-특이 항체 및 T-세포 반응: 종단 코호트 연구

Article

Published on 2022-05-012022-09-11
Journal: The Lancet. Microbe
[Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료기술,

[키워드] Academy age analysed antibody Antibody Response antibody titres B.1.351 B.1.617.2 Beta Beta variant breadth caused center Chinese collected communicable disease Communicable Disease Diagnosis COVID-19 Critical cross-reactive cytokine cytokine profile D614G D614G variant delta variant Delta variants detect detectable discharged disease disease severity ELISA ELISPOT enrolled enzyme evaluated Follow-up Follow-up visit follow-up visits foundation humoral humoral and T-cell response ICS IFN-γ IFNγ IgA IgG antibodies IgG antibody IgM IL-2 immune immune response In-vitro individual individuals Infection initial interferon interferon γ interleukin interleukin-2 intracellular cytokine staining longitudinal cohort study magnitude Medical Research Council Medical Sciences memory memory immune response memory T-cell response memory T-cell responses microneutralisation assay natural Necrosis neutralising Neutralising Antibodies neutralising antibody neutralising antibody response Neutralising antibody responses neutralising antibody titre neutralising antibody titres no difference not disrupted participant Patient patients patients with moderate PBMC PBMCs plasma plasma sample plasma samples Protein Receptor-binding domain recovered patient recovered patients recruited reduce reduced reducing reduction Reinfection remained retained robustness SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleoprotein SARS-CoV-2 strain SARS-CoV-2 viral SARS-CoV-2-specific T-cell response Science severe disease spike Spike protein subset symptom severity Symptoms T-cell Response T-cell responses tested the interferon the receptor-binding domain the SARS-CoV-2 titre TNFα tumour necrosis factor Tumour Necrosis Factor α variant variants variants of concern Viral proteins viral strain viral strains Wuhan Wuhan, China
[DOI] 10.1016/S2666-5247(22)00036-2 PMC 바로가기 [Article Type] Article

SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022

SARS-CoV-2 Omicron 변이체 BA.2 중화, Comirnaty 또는 CoronaVac 백신 접종, 감염 또는 돌발성 감염, 홍콩, 2020년에서 2022년까지

Article

Published on 2022-05-012022-09-11
Journal: Eurosurveillance
[Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] affecting antibody Beta BNT162b2 Breakthrough infection breakthrough infections circulation comparable CoronaVac Delta detectable dose elicited evaluated followed by help Hong Kong hybrid-immunity individual individuals Infection neutralisation neutralisation test neutralisation tests Neutralising Antibodies neutralising antibody neutralising antibody response neutralising antibody titre neutralising antibody titres neutralization omicron other variant other variants PRNT reduction response SARS-CoV-2 SARS-COV-2 infection sera significantly single vaccine subvariant BA.1 subvariant BA.2 symptomatic infection titre titres uninfected vaccination Vaccine vaccine. vaccinee vaccinees variant viruses wild type
[DOI] 10.2807/1560-7917.ES.2022.27.18.2200178 PMC 바로가기 [Article Type] Article

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과

Clinical Trial

Published on 2022-05-012022-09-11
Journal: The Lancet. Infectious Diseases
[Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no
[DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종

Clinical Trial

Published on 2022-02-052022-08-13
Journal: Lancet (London, England)
[Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine
[DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형

Research Article

Published on 2021-12-022022-08-13
Journal: PLoS Pathogens
[Category] Biochemistry, SARS, 변종, 진단,

[키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article

Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme—The South African Experience

Covid-19 회복기 플라즈마 프로그램의 신속하고 성공적인 구현-남아프리카 경험

Article

Published on 2021-10-122022-09-01
Journal: Viruses
[Category] MERS, SARS, 진단,